A003060 Stock Overview
Manufactures and sells pharmaceutical products primarily in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Aprogen Biologics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩644.00 |
| 52 Week High | ₩3,080.00 |
| 52 Week Low | ₩611.00 |
| Beta | 0.0066 |
| 1 Month Change | -20.79% |
| 3 Month Change | -29.46% |
| 1 Year Change | -77.79% |
| 3 Year Change | -92.88% |
| 5 Year Change | -95.30% |
| Change since IPO | -99.93% |
Recent News & Updates
Risks Still Elevated At These Prices As Aprogen Biologics Inc. (KRX:003060) Shares Dive 26%
Jun 20
More Unpleasant Surprises Could Be In Store For Aprogen Biologics Inc.'s (KRX:003060) Shares After Tumbling 28%
Apr 18Recent updates
Risks Still Elevated At These Prices As Aprogen Biologics Inc. (KRX:003060) Shares Dive 26%
Jun 20More Unpleasant Surprises Could Be In Store For Aprogen Biologics Inc.'s (KRX:003060) Shares After Tumbling 28%
Apr 18We Wouldn't Rely On Aprogen pharmaceuticalsInc's (KRX:003060) Statutory Earnings As A Guide
Jan 16Aprogen pharmaceuticals,Inc.'s (KRX:003060) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Dec 20
Is Aprogen pharmaceuticalsInc (KRX:003060) A Risky Investment?
Nov 24Shareholder Returns
| A003060 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -8.4% | -0.5% | -1.9% |
| 1Y | -77.8% | 0.8% | -9.5% |
Return vs Industry: A003060 underperformed the KR Pharmaceuticals industry which returned 0.8% over the past year.
Return vs Market: A003060 underperformed the KR Market which returned -9.5% over the past year.
Price Volatility
| A003060 volatility | |
|---|---|
| A003060 Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.8% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A003060 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A003060's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1960 | 363 | Jeong-Chool Kim | en.aprogen-pharm.com/index.do |
Aprogen Biologics Inc. manufactures and sells pharmaceutical products primarily in South Korea. It offers approximately 200 types of medicines, including ethical and over the counter drugs. The company offers its drugs for transfusion, digestive system, osteoarthritis, skeletal muscle relaxants, NSAIDs, osteoporosis, circulatory system, endocrine, respiratory system, urinary system, depilatory, antihistamines and antiallergics, obesity, brain function, neurologics, and male pattern hair loss.
Aprogen Biologics Inc. Fundamentals Summary
| A003060 fundamental statistics | |
|---|---|
| Market cap | ₩130.00b |
| Earnings (TTM) | -₩141.77b |
| Revenue (TTM) | ₩68.03b |
1.9x
P/S Ratio-0.9x
P/E RatioIs A003060 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A003060 income statement (TTM) | |
|---|---|
| Revenue | ₩68.03b |
| Cost of Revenue | ₩71.66b |
| Gross Profit | -₩3.63b |
| Other Expenses | ₩138.15b |
| Earnings | -₩141.77b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -717.58 |
| Gross Margin | -5.33% |
| Net Profit Margin | -208.39% |
| Debt/Equity Ratio | 24.5% |
How did A003060 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 20:09 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aprogen Biologics Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|